The historical rank and industry rank for Anavex Life Sciences's PB Ratio or its related term are showing as below:
AVXL'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 28.41
Current: 2.05
During the past 13 years, Anavex Life Sciences's highest PB Ratio was 28.41. The lowest was 0.00. And the median was 0.00.
AVXL's PB Ratio is ranked better than 55.45% of 1311
companies
in the Biotechnology industry
Industry Median: 2.37
vs AVXL: 2.05
During the past 12 months, Anavex Life Sciences's average Book Value Per Share Growth Rate was -4.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 57.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 43.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Anavex Life Sciences was 227.10% per year. The lowest was -528.30% per year. And the median was 20.10% per year.
Back to Basics: PB Ratio
Anavex Life Sciences PB Ratio Historical Data
The historical data trend for Anavex Life Sciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Anavex Life Sciences's PB Ratio
For the Biotechnology subindustry, Anavex Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anavex Life Sciences's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Anavex Life Sciences's PB Ratio falls into.
Anavex Life Sciences PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Anavex Life Sciences (NAS:AVXL) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Anavex Life Sciences PB Ratio Related Terms
Thank you for viewing the detailed overview of Anavex Life Sciences's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Anavex Life Sciences (Anavex Life Sciences) Business Description
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AVXL has been successfully added to your 